君实生物：与德琪医药达成战略合作，共同开展JS207（PD-1/VEGF双抗）与ATG-037（CD73口服小分子抑制剂）联合用药研究

Core Viewpoint - Junshi Biosciences has announced a strategic collaboration with Eucure Biopharma to explore the synergistic potential of their respective cancer treatments in mainland China [1] Group 1: Collaboration Details - The collaboration focuses on Junshi's JS207, a dual-specific antibody targeting PD-1 and VEGF, and Eucure's ATG-037, an oral CD73 small molecule inhibitor [1] - The partnership aims to investigate the combined therapeutic effects of these two innovative treatments on tumor patients [1] Group 2: Product Information - JS207 is a recombinant humanized dual-specific antibody that has shown promising anti-tumor activity and controllable safety profiles in both preclinical and clinical studies [1] - Preclinical studies have validated its significant anti-tumor efficacy across multiple tumor models and support its differentiated mechanism of action [1] - Research indicates that VEGFA can enhance the antigen-binding activity of JS207, T-cell activation efficacy, and the internalization of PD-1 on the cell surface [1]